Human γδ T cells as mediators of chimaeric-receptor redirected anti-tumour immunity

British Journal of Haematology

Volumn 126, Issue 4, 2004, Pages 583-592

  Rischer, Markus ^a   Pscherer, Sibylle ^a   Duwe, Susanne ^a   Vormoor, Josef ^a   Jürgens, Heribert ^a   Rossig, Claudia ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Adoptive immunotherapy; Gene therapy; T cell receptor; T lymphocytes

Indexed keywords

ALPHA INTERFERON; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; CHIMERIC PROTEIN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; EPITOPE; GAMMA INTERFERON; IMIDAZOLE DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL TRANSFER; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; TARGET CELL; TUMOR CELL; ADOPTIVE IMMUNOTHERAPY; BIOSYNTHESIS; BLOOD; CELL DIVISION; CYTOTOXICITY; DRUG EFFECT; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; METHODOLOGY; NEOPLASM; RETROVIRUS; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, NEOPLASM; CELL DIVISION; CYTOTOXICITY, IMMUNOLOGIC; DIPHOSPHONATES; EPITOPES, T-LYMPHOCYTE; HUMANS; IMIDAZOLES; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RETROVIRIDAE; T-LYMPHOCYTE SUBSETS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 4143074668     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05077.x     Document Type: Article

References (62)

1. Altenschmidt, U., Klundt, E. & Groner, B. (1997) Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumour regression. Journal of Immunology, 159, 5509-5515.
2. Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J.H., Lanier, L.L. & Spies, T. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress- inducible MICA. Science, 285, 727-729.
3. Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M.J., Blacklock, H.A., Bell, R., Simeone, J., Reitsma, D.J., Heffernan, M., Seaman, J. & Knight, R.D. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. New England Journal of Medicine, 334, 488-493.
4. Berenson, J.R., Major, P. & Hortabagyi, G. (1998) Relevant clinical end points in biphosphonate trials. Journal of Clinical Oncology, 16, 3204-3205.
5. Boismenu, R. & Havran, W.L. (1998) Gammadelta T cells in host defense and epithelial cell biology. Clinical Immunology and Immunopathology, 86, 121-133.
6. Bretscher, P. & Cohn, M. (1970) A theory of self-nonself discrimination. Science, 169, 1042-1049.
7. Brocker, T. (2000) Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood, 96, 1999-2001.
8. Brocker, T. & Karjalainen, K. (1995) Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. Journal of Experimental Medicine, 181, 1653-1659.
9. Bukowski, J.F., Morita, C.T., Tanaka, Y., Bloom, B.R., Brenner, M.B. & Band, H. (1995) V gamma 2V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. Journal of Immunology, 154, 998-1006.
10. Burk, M.R., Mori, L. & De Libero, G. (1995) Human V gamma 9-V delta 2 cells are stimulated in a cross-reactive fashion by a variety of phosphorylated metabolites. European Journal of Immunology, 25, 2052-2058.
11. Burk, M.R., Carena, I., Donda, A., Mariani, F., Mori, L. & DeLibero, G. (1997) Functional inactivation in the whole population of human V gamma 9/V delta 2 T lymphocytes induced by a nonpeptidic antagonist. Journal of Experimental Medicine, 185, 91-97.
12. Chen, J., Niu, H., He, W. & Ba, D. (2001) Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes. International Archives of Allergy and Immunology, 125, 256-263.
13. Choudhary, A., Davodeau, F., Moreau, A., Peyrat, M.A., Bonneville, M. & Jotereau, F. (1995) Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma. Journal of Immunology, 154, 3932-3940.
14. Collins, R.H., Goldstein, S., Giralt, S., Levine, J., Porter, D., Drobyski, W., Barrett, J., Johnson, M., Kirk, A., Horowitz, M. & Parker, P. (2000) Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplantation, 26, 511-516.
15. Das, H., Groh, V., Kuijl, C., Sugita, M., Morita, C.T., Spies, T. & Bukowski, J.F. (2001a) MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity, 15, 83-93.
16. Das, H., Wang, L., Kamath, A. & Bukowski, J.F. (2001b) Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood, 98, 1616-1618.
17. Dhodapkar, M.V., Singh, J., Mehta, J., Fassas, A., Desikan, K.R., Perlman, M., Munshi, N.C. & Barlogie, B. (1998) Anti-myeloma activity of pamidronate in vivo. British Journal of Haematology, 103, 530-532.
18. Dieli, F., Gebbia, N., Poccia, F., Caccamo, N., Montesano, C., Fulfaro, F., Arcara, C., Valerio, M.R., Meraviglia, S., Di Sano, C., Sireci, G. & Salemo, A. (2003) Induction of gamma delta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood, 102, 2310-2311.
19. Eberl, M., Engel, R., Beck, E. & Jomaa, H. (2002) Differentiation of human gamma delta T cells towards distinct memory phenotypes. Cellular Immunology, 218, 1-6.
20. Ferrarini, M., Heltai, S., Toninelli, E., Sabbadini, M.G., Pellicciari, C. & Manfredi, A.A. (1995) Daudi lymphoma killing triggers the programmed death of cytotoxic V-gamma-9/V-delta-2 T-lymphocytes. Journal of Immunology, 154, 3704-3712.
21. Fisch, P., Malkovsky, M., Kovats, S., Sturm, E., Braakman, E., Klein, B.S., Voss, S.D., Morrissey, L.W., DeMars, R., Welch, W.J., Bolhuis, R.L.H. & Sondel, P.M. (1990) Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. Science, 250, 1269-1273.
22. Gioia, C., Agrati, C., Casetti, R., Cairo, C., Borsellino, G., Battistini, L., Mancino, G., Goletti, D., Colizzi, V., Pucillo, L.P. & Poccia, F. (2002) Lack of CD27(-)CD45RA-V gamma 9V delta 2(+) T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. Journal of Immunology, 168, 1484-1489.
23. Gober, H.J., Kistowska, M., Angman, L., Jeno, P., Mori, L. & De Libero, G. (2003) Human T cell receptor gamma delta cells recognize endogenous mevalonate metabolites in tumor cells. Journal of Experimental Medicine, 197, 163-168.
24. Hanenberg, H., Xiao, X.L., Dilloo, D., Hashino, K., Kato, I. & Williams, D.A. (1996) Colocalizarion of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nature Medicine, 2, 876-882.
25. Hwu, P., Shafer, G.E., Treisman, J., Schindler, D.G., Gross, G., Cowherd, R., Rosenberg, S.A. & Eshhar, Z. (1993) Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. Journal of Experimental Medicine, 178, 361-366.
26. Janssen, O., Wesselborg, S., Heckl-Ostreicher, B., Pechhold, K., Bender, A., Schondelmaier, S., Moldenhauer, G. & Kabelitz, D. (1991) T cell receptor/CD3-signaling induces death by apoptosis in human T cell receptor gamma delta+ T cells. Journal of Immunology, 146, 35-39.
27. Kato, Y., Tanaka, Y., Miyagawa, F., Yamashita, S. & Minato, N. (2001) Targeting of tumor cells for human gammadelta T cells by non-peptide antigens. Journal of Immunology, 167, 5092-5098.
28. Kershaw, M.H., Westwood, J.A. & Hwu, P. (2002) Dual-specific T cells combine proliferation and antitumor activity. Nature Biotechnology, 20, 1221-1227.
29. Kinsella, T.M. & Nolan, G.P. (1996) Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Human Gene Therapy, 7, 1405-1413.
30. Kunzmann, V., Bauer, E., Feurle, J., Weissinger, F., Tony, H.P. & Wilhelm, M. (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood, 96, 384-392.
31. Lopez, R.D., Xu, S., Guo, B., Negrin, R.S. & Waller, E.K. (2000) CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. Blood, 96, 3827-3837.
32. Lozupone, F., Pende, D., Burgio, V.L., Castelli, C., Spada, M., Venditti, M., Luciani, F., Lugini, L., Federici, C., Ramoni, C., Rivoltini, L., Parmiani, G., Belardelli, F., Rivera, P., Marcenaro, S., Moretta, L. & Fais, S. (2004) Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res, 64, 378-385.
33. Maher, J., Brennens, R.J., Gunset, G., Riviere, I. & Sadelain, M. (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nature Biotechnology, 20, 70-75.
34. McCloskey, E.V., MacLennan, I.C., Drayson, M.T., Chapman, C., Dunn, J. & Kanis, J.A. (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. British Journal of Haematology, 100, 317-325.
35. McGuinness, R.P., Ge, Y., Patel, S.D., Kashmiri, S.V., Lee, H.S., Hand, P.H., Schlom, J., Finer, M.H. & McArthur, J.G. (1999) Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor [see comments]. Human Gene Therapy, 10, 165-173.
36. Mitsuyasu, R.T., Anton, P.A., Deeks, S.G., Scadden, D.T., Connick, E., Downs, M.T., Bakker, A., Roberts, M.R., June, C.H., Jalali, S., Lin, A.A., Pennathur-Das, R. & Hege, K.M. (2000) Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood, 96, 785-793.
37. Morita, C.T., Beckman, E.M., Bukowski, J.F., Tanaka, Y., Band, H., Bloom, B.R., Golan, D.E. & Brenner, M.B. (1995) Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. Immunity, 3, 495-507.
38. Mujoo, K., Kipps, T.J., Yang, H.M., Cheresh, D.A., Wargalla, U., Sander, D.J. & Reisfeld, R.A. (1989) Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Research, 49, 2857-2861.
39. Nanno, M., Seki, H., Mathioudakis, G., Suzuki, R., Itoh, K., Ioannides, C.G., Suzuki, S., Chen, P.F. & Platsoucas, C.D. (1992) Gamma/delta T cell antigen receptors expressed on tumor-infiltrating lymphocytes from patients with solid tumors. European Journal of Immunology, 22, 679.
40. Nicholson, I.C., Lenton, K.A., Little, D.J., Decorso, T., Lee, F.T., Scott, A.M., Zola, H. & Hohmann, A.W. (1997) Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Molecular Immunology, 34, 1157-1165.
41. Riviere, I., Brose, K. & Mulligan, R.C. (1995) Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proceedings of the National Academy of Sciences of the United States of America, 92, 6733-6737.
42. Roessig, C., Scherer, S.P., Baer, A., Vormoor, J., Rooney, C.M., Brenner, M.K. & Juergens, H. (2002) Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Annals of Hematology, 81(Suppl. 2), S42-S43.
43. Rooney, C.M., Smith, C.A., Ng, C.Y., Loftin, S., Li, C., Krance, R.A., Brenner, M.K. & Heslop, H.E. (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein- Barr-virus-related lymphoproliferation. Lancet, 345, 9-13.
44. Rooney, C.M., Smith, C.A., Ng, C.Y., Loftin, S.K., Sixbey, J.W., Gan, Y., Srivastava, D.K., Bowman, L.C., Krance, R.A., Brenner, M.K. & Heslop, H.E. (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92, 1549-1555.
45. Roskrow, M.A., Suzuki, N., Gan, Y., Sixbey, J.W., Ng, C.Y., Kimbrough, S., Hudson, M., Brenner, M.K., Heslop, H.E. & Rooney, C.M. (1998) Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood, 91, 2925-2934.
46. Rossig, C., Bollard, C.M., Nuchtern, J.G., Merchant, D.A. & Brenner, M.K. (2001) Targeting of G (D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. International Journal of Cancer, 94, 228-236.
47. Rossig, C., Bollard, C.M., Nuchtern, J.G., Rooney, C.M. & Brenner, M.K. (2002) Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood, 99, 2009-2016.
48. Rothenfusser, S., Buchwald, A., Kock, S., Ferrone, S. & Fisch, P. (2002) Missing HLA class I expression on Daudi cells unveils cytotoxic and proliferative responses of human gammadelta T lymphocytes. Cell Immunology, 215, 32-44.
49. Sadelain, M., Riviere, I. & Brentjens, R. (2003) Targeting tumours with genetically enhanced T lymphocytes. Nature Reviews Cancer, 3, 35-45.
50. Schilbach, K., Geiselhart, A. & Handgretinger, R. (2001) Induction of proliferation and augmented cytotoxicity of gammadelta T lymphocytes by bisphosphonate clodronate. Blood, 97, 2917-2918.
51. Schild, H., Mavaddat, N., Litzenberger, C., Ehrich, E.W., Davis, M.M., Bluestone, J.A., Malis, L., Draper, R.K. & Chien, Y.H. (1994) The nature of major histocompatibility complex recognition by gamma delta T cells. Cell, 76, 29-37.
52. Schulz, G., Cheresh, D.A., Varki, N.M., Yu, A., Staffileno, L.K. & Reisfeld, R.A. (1984) Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Research, 44, 5914-5920.
53. Sen, G., Chakraborty, M., Foon, K.A., Reisfeld, R.A. & Bhattacharya-Chatterjee, M. (1997) Preclinical evaluation in nonhuman primates of murine monoclonal anti- idiotype antibody that mimics the disialoganglioside GD2. Clinical Cancer Research, 3, 1969-1976.
54. Sicard, H., Al Saati, T., Delsol, G. & Fournie, J.J. (2001) Synthetic phosphoantigens enhance human Vgamma9Vdelta2 T lymphocytes killing of non-Hodgkin's B lymphoma. Molecular Medicine, 7, 711-722.
55. Tanaka, Y., Morita, C.T., Tanaka, Y., Nieves, E., Brenner, M.B. & Bloom, B.R. (1995) Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature, 375, 155-158.
56. Thomas, M.L., Samant, U.C., Deshpande, R.K. & Chiplunkar, S.V. (2000) Gamma delta T cells lyse autologous and allogenic oesophageal tumours: involvement of heat-shock proteins in the tumour cell lysis. Cancer Immunology, Immunotherapy, 48, 653-659.
57. Watanabe, N., Hizuta, A., Tanaka, N. & Orita, K. (1995) Localization of T cell receptor (TCR)-gamma delta+ T cells into human colorectal cancer: flow cytometric analysis of TCR-gamma delta expression in tumour-infiltrating lymphocytes. Clinical and Experimental Immunology, 102, 167-173.
58. Weber, J.S., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., White, D.E. & Rosenberg, S.A. (1992) The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology, 10, 33-40.
59. Wilhelm, M., Kunzmann, V., Eckstein, S., Reimer, P., Weissinger, F., Ruediger, T. & Tony, H.P. (2003) gamma delta T cells for immune therapy of patients with lymphoid malignancies. Blood, 102, 200-206.
60. Wu, J., Chalupny, N.J., Manley, T.J., Riddell, S.R., Cosman, D. & Spies, T. (2003) Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. Journal of Immunology, 170, 4196-4200.
61. Zheng, B.J., Chan, K.W., Im, S., Chua, D., Sham, J.S., Tin, P.C., He, Z.M. & Ng, M.H. (2001) Anti-tumor effects of human peripheral gammadelta T cells in a mouse tumor model. International Journal of Cancer, 92, 421-425.
62. Zocchi, M.R., Ferrarini, M. & Rugarli, C. (1990) Selective lysis of the autologous tumor by delta TCS1+ gamma/delta+ tumor-infiltrating lymphocytes from human lung carcinomas. European Journal of Immunology, 20, 2685-2689.